Adherence to Therapy: Using an Evidence-Based Protocol


  • Linda A. Moore EdD APRN BC ANP/GNP MSCN,

    Associate Professor, Corresponding author
    Search for more papers by this author
    • Linda A. Moore, EdD APRN BC ANP/GNP MSCN, is an associate professor and nurse practitioner at UNC Charlotte, College of Health and Human Services & the Multiple Sclerosis Center, Carolinas HealthCare System in Charlotte, NC.

  • Michael D. Kaufman MD,

    Medical DirectorSearch for more papers by this author
    • Michael D. Kaufman, MD, is a medical director in the MS Center, Carolina Healthcare System, Charlotte, NC.

  • Robert Algozzine PhD,

    ProfessorSearch for more papers by this author
    • Robert Algozzine, PhD, is a professor at UNC Charlotte School of Education.

  • Nikki Irish MSN APRN BC ANP,

    Nurse Practitioner and Professional EducatorSearch for more papers by this author
    • Nikki Irish, MSN APRN BC ANP, is a nurse practitioner and professional educator.

  • Mary Martin LPN,

    Search for more papers by this author
    • Mary Martin is an LPN at Raleigh University.

  • Carol Rosser Posey MSN APRN ANP

    Nurse PractitionerSearch for more papers by this author
    • Carol Rosser Posey, MSN APRN ANP, is a nurse practitioner at Advanced Occupational Health Services.


The number of patients receiving injectable medications has increased significantly during the past few years. Today, patients with hepatitis, rheumatoid arthritis, and multiple sclerosis are added to the list of those, namely diabetics, who have been instructed in self-administration of injectable medications. Currently, some of these medications create significant skin site reactions, and patients tend to discontinue the medications without informing the healthcare provider. Determining the problem and developing a research study that provides evidence to demonstrate methods to help patients adhere to agreed-upon treatment modalities can be accomplished within the clinical practice setting. This study provided a method to decrease skin reactions with interferon 1-b injections for multiple sclerosis patients and has been continued as a method with other like medications.